Dormagen
Germany
46
2025-11-27
The entities that hold a legal rights for patent applications filed by inventor Greven Simone:
Simone Greven from Dormagen, DE has applied for patents for these inventions. The list has both pending applications and granted patents:
ATRIAL NATRIURETIC PEPTIDE ENGRAFTED ANTIBODIES
#2 | 2025-03-27Active Metabolites of Kinesin Spindle Protein Inhibitor Conjugates
#3 | 2024-02-08PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS
#4 | 2023-12-14SPECIFIC ANTIBODY-DRUG-CONJUGATES (ADCS) WITH KSP INHIBITORS AND ANTI-CD123-ANTIBODIES
#5 | 2023-10-26ANTIBODY DRUG CONJUGATES (ADCS) HAVING ENZYMATICALLY CLEAVABLE GROUPS
#6 | 2023-02-09Antibody drug conjugates with enzymatically cleavable groups
#7 | 2022-08-25Specific antibody-drug-conjugates (ADCs) with KSP inhibitors and anti-CD123-antibodies
#8 | 2022-01-20Antibody drug conjugates (ADCS) having enzymatically cleavable groups
#9 | 2021-09-09BINDER/ACTIVE AGENT CONJUGATES DIRECTED AGAINST CXCR5, HAVING ENZYMATICALLY CLEAVABLE LINKERS AND IMPROVED ACTIVITY PROFILE
#10 | 2021-08-19Site specific homogeneous with KSP inhibitors
#11 | 2021-07-29SPECIFIC ANTIBODY-DRUG-CONJUGATES (ADCS) WITH KSP INHIBITORS AND ANTI-CD123-ANTIBODIES
#12 | 2021-05-13ATRIAL NATRIURETIC PEPTIDE ENGRAFTED ANTIBODIES
#13 | 2020-11-19ANTIBODY DRUG CONJUGATES (ADCS) WITH NAMPT INHIBITORS
#14 | 2020-05-07Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with antiB7H3-antibodies
#15 | 2019-11-21Prodrugs of cytotoxic active agents having enzymatically cleavable groups
#16 | 2019-10-31Specific antibody-drug-conjugates (ADCs) with KSP inhibitors and anti-CD123-antibodies
#17 | 2019-10-31Antibody drug conjugates (ADCs) having enzymatically cleavable groups
#18 | 2019-08-29Site specific homogeneous with KSP inhibitors
#19 | 2019-03-14Prodrugs of cytotoxic active agents having enzymatically cleavable groups
#20 | 2018-11-08ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-TWEAKR-ANTIBODIES
#21 | 2018-11-08Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with anti-CD123-antibodies
#22 | 2018-07-05ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-B7H3-ANTIBODIES
#23 | 2018-06-21Antibody drug conjugates (ADCS) and antibody prodrug conjugates (APDCS) with enzymatically cleavable groups
#24 | 2018-01-18Antibody-drug conjugates (ADCs) of KSP inhibitors with aglycosylated anti-TWEAKR antibodies
#25 | 2017-06-08ANTI-C4.4A ANTIBODIES AND USES THEREOF
#26 | 2016-12-01Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP)
#27 | 2016-11-03Neutralizing prolactin receptor antibody Mat3 and its therapeutic use
#28 | 2016-08-18ANTI-TWEAKR ANTIBODIES AND USES THEREOF
#29 | 2016-07-07NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF
#30 | 2016-01-14PDGFRBETA-FC FUSION PROTEINS AND USES THEREOF
#31 | 2015-09-03NOVEL BINDER-DRUG CONJUGATES (ADCs) AND USE OF SAME
#32 | 2015-01-29NOVEL BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF
#33 | 2015-01-22NEW ANTIBODY DRUG CONJUGATES (ADCS) AND THE USE THEREOF
#34 | 2014-10-30Anti-FGFR2 Antibodies and Uses Thereof
#35 | 2014-05-22Neutralizing prolactin receptor antibody Mat3 and its therapeutic use
#36 | 2014-05-08Novel Binder-Drug Conjugates (ADCs) and Use of Same
#37 | 2014-02-20BINDING PROTEINS TO INHIBITORS OF COAGULATION FACTORS
#38 | 2013-10-17Neutralizing prolactin receptor antibodies and their therapeutic use
#39 | 2013-07-04NEUTRALIZING PROLACTIN RECEPTOR ANTIBODIES AND THEIR THERAPEUTIC USE
#40 | 2013-05-23Neutralizing prolactin receptor antibodies and their therapeutic use
#41 | 2013-05-16NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF
#42 | 2013-04-18Binder-drug conjugates (ADCs) and use thereof
#43 | 2013-03-14NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF
#44 | 2013-01-24NEUTRALIZING PROLACTIN RECEPTOR ANTIBODIES AND THEIR THERAPEUTIC USE
#45 | 2012-12-20ANTI-C4.4A ANTIBODIES AND USES THEREOF
#46 | 2009-07-02Chimeric Kunitz Domains and their Use
52399 ⎘